Today 2026.06.10 D-93
Today 
|
Plenary Session 1 CAR T Cell Therapy Sep. 17 (Thu), 10:30-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL
Children's Hospital of Philadelphia, USA
Eliminating GVHD Prophylaxis: A New Era of Sequential CAR-T and Allogeneic HSCT
The First Affiliated Hospital, Zhejiang University School of Medicine, China
|
Plenary Session 2 GVHD Sep. 17 (Thu), 13:00-14:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Beyond Immunosuppression: Enhancing Tissue Resilience to Mitigate GVHD
Dan L. Duncan Comprehensive Cancer Center, USA
Immunologic Mechanisms and Modulation of Graft-Versus-Host Disease
University of Minnesota, USA
|
Joint Symposium 1 (ASTCT-KSBMT) Evolving T-cell Manipulation Strategies: Optimization of PTCy and New Frontiers in T Cell Depletion Sep. 17 (Thu), 14:30-16:00 |
Room A (1F) |
|
|---|---|---|
TBD
University of Minnesota, USA
TBD
Fred Hutchinson Cancer Center, USA
TBD
TBD, TBD
|
Scientific Session 1 Next-Generation Immune Effector Cell Therapies: Emerging Platforms and Biological Insights Sep. 17 (Thu), 14:30-16:00 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea) |
|
Biomarkers and Immune Fitness Shaping Outcomes of Immune Effector Cell Therapies
Dana-Farber Cancer Institute, USA
In Vivo CAR-T Engineering for Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells
University of Ulsan College of Medicine, Korea
|
Scientific Session 2 Advances in Immunotherapy and Transplant Strategies in Pediatric Hematologic Malignancies Sep. 17 (Thu), 14:30-16:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea) Jun Eun Park (Korea University College of Medicine, Korea) |
|
Virus-specific T Cells for Adoptive Immunotherapy
Dana-Farber Cancer Institute, USA
Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL
Wroclaw Medical University, Poland
Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies
Sungkyunkwan University School of Medicine, Korea
|
Education Session 1 Additional Cellular Support after Allogeneic Transplantation Sep. 17 (Thu), 14:30-16:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea) Hyoung Soo Choi (Seoul National University College of Medicine, Korea) |
|
Management of Poor Graft Function in Chilren
Korea University College of Medicine, Korea
Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs
University of Ulsan College of Medicine, Korea
Cellular Support Beyond the Graft: Integrative Strategis after Allogeneic HSCT
Case Western Reserve University School of Medicine, USA
|
Joint Symposium 2 (EBMT-KSBMT) Evolving Donor Issues in Allogeneic HSCT: From HLA Matching to Germline Screening and Emerging Concerns Sep. 17 (Thu), 16:50-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ibrahim Yakoub-Agha (Lille University Hospital, France) | |
TBD
University of Tor Vergata, Italy
Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia?
La Fe University and Polytechnic Hospital, Spain
TBD
TBD, TBD
TBD
University of Ulsan College of Medicine, Korea
|
Scientific Session 3 Post-Transplant Residual Disease in Acute Leukemia: Monitoring and Therapeutic Strategies Sep. 17 (Thu), 16:50-18:20 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Myungshin Kim (The Catholic University of Korea, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea) |
|
Flow Cytometric MRD for AML: Updates in 2026
Amsterdam UMC, The Netherlands
Targeting Residual Disease after Transplant: The Convergence of HSCT and Engineered Cellular Therapies
Columbia University Irving Medical Center, USA
Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients
Yonsei University College of Medicine, Korea
|
Scientific Session 4 Science Behind Treatment Response and Relapse Sep. 17 (Thu), 16:50-18:20 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Won-Sik Lee (Inje University College of Medicine, Korea) Sung-Soo Yoon (Seoul National University College of Medicine, Korea) |
|
Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML
UNIST, Korea
Mechanism of Immune Evasion in AML
Vanderbilt University Medical Center, USA
Immune Escape as a Mechanism of Post-transplant Relapse
Taussig Cancer Institute, USA
